Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines

Guy de Bruyn MD,^{*1} Joyce Wang MS,² Annie Purvis MSPH,³ Martin Sanchez Ruiz MD,⁴ Haritha Adhikarla PhD,¹ Saad Alvi MD,⁵ Matthew I Bonaparte PhD,¹ Daniel Brune MD,⁶ Agustin Bueso MD,⁷ Richard M Canter MS,¹ Maria Angeles Ceregido PhD,⁸ Sachin Deshmukh MD,⁹ David Diemert MD,¹⁰ Adam Finn MD,¹¹ Remi Forrat MD,¹² Bo Fu PhD,¹ Julie Gallais MS,¹² Paul Griffin MBBS,¹³ Marie-Helene Grillet MD,¹⁴ Owen Haney PharmD,¹ Jeffrey A Henderson MD,¹⁵ Marguerite Koutsoukos MS,⁸ Odile Launay MD,¹⁶ Federico Martinon Torres MD¹⁷ Roger Masotti MS,¹ Nelson L Michael MD,¹⁸ Juliana Park MD,¹⁹ Doris M Rivera M MD,²⁰ Natalya Romanyak PharmD,¹ Chris Rook MB,²¹ Lode Schuerman MD,⁸ Lawrence D Sher MD,²² Fernanda Tavares-Da-Silva MD,⁸⁺ Ashley Whittington MD,²³ Roman M Chicz PhD,³ Sanjay Gurunathan MD,¹ Stephen Savarino MD,¹⁺ Saranya Sridhar DPhil²⁴ on behalf of the VAT00002 booster cohorts study team.[‡]

- 1. Sanofi, Swiftwater, PA, USA
- 2. Sanofi, Chengdu, China
- 3. Sanofi, Cambridge, MA, USA
- 4. Sanofi, Paris, France
- 5. Chicago Clinical Research Institute, IL, USA
- 6. Optimal Research, Peoria, IL, USA
- 7. Demedica, San Pedro Sula, Honduras
- 8. GSK, Wavre, Belgium
- 9. Griffith University, Australia
- 10. School of Medicine and Health Sciences, George Washington University, Washington, DC, USA
- 11. Bristol Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine, University of Bristol, Bristol, UK
- 12. Sanofi, Marcy l'Etoile, France
- 13. Mater Health, Brisbane, Queensland, Australia. The University of Queensland, Brisbane, Queensland, Australia
- 14. Sanofi, Lyon, France
- 15. Black Hills Center for American Indian Health, SD, USA
- 16. Université Paris Cité; Inserm, F-CRIN I REIVAC, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
- 17. Pediatrics Department, Translational Pediatrics and Infectious Diseases Section, Santiago de Compostela, Spain; Genetics- Vaccines- Infectious Diseases and Pediatrics research group GENVIP, Instituto de Investigación Sanitaria de Santiago (IDIS), Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.

- 18. Walter Reed Army Institute of Research, Silver Spring, MD, USA
- 19. Sanofi, Sydney, Australia
- 20. INVERIME S.A, Tegucigalpa, Honduras
- 21. Cmax, Adelaide, Australia
- 22. Peninsula Research Associates, Rolling Hills Estates, CA, USA
- 23. London North West University Healthcare NHS Trust, London, UK
- 24. Sanofi, Reading, UK

*Corresponding Author: Guy de Bruyn, Sanofi, Swiftwater, PA, USA, Guy.DeBruyn@sanofi.com; Tel:

+15709725671

[†]Affiliation at time of study conduct.

^{*}VAT00002 booster cohorts study team members are listed in the Supplementary Appendix

1 Abstract

2 Background

3 Booster vaccines providing protection against emergent SARS-CoV-2 variants are needed. In an

- 4 international phase 3 study, we evaluated booster vaccines containing prototype (D614) and/or Beta
- 5 (B.1.351) variant recombinant spike proteins and AS03 adjuvant (CoV2 preS dTM-AS03).
- 6 Methods

7 Adults, primed 4–10 months earlier with mRNA (BNT162b2, mRNA-1273]), adenovirus-vectored 8 (Ad26.CoV2.S, ChAdOx1nCoV-19) or adjuvanted protein (CoV2 preS dTM-AS03 [D614]) vaccines and 9 stratified by age (18-55 and \geq 56 years), were boosted with monovalent (MV) D614 (5µg, n=1285), 10 MV (B.1351) (5μg, n=707) or bivalent (BiV) (2.5μg D614 plus 2.5μg B.1.351, n=625) CoV2 preS dTM-11 AS03. SARS-CoV-2-naïve adults (controls, n=479) received a primary series (two injections, 21 days 12 apart) of CoV2 preS dTM-AS03 containing 10µg D614. Antibodies to D614G, B.1.351 and Omicron 13 BA.2 and BA.1 variants were evaluated using validated pseudovirus (lentivirus) neutralization (PsVN) 14 assay. D614G or B.1.351 PsVN titers 14 days (D15) post-booster were compared with pre-booster 15 (D1) titers in BNT162b2-primed participants (18-55 years old) and controls (D36), for each booster 16 formulation (co-primary objectives). Safety was evaluated throughout the trial. Results of a planned 17 interim analysis are presented.

18 Results

Among BNT162b2-primed adults (18-55 years old), PsVN titers against D614G or B.1.351 were significantly higher post-booster than anti-D614G titers post-primary vaccination in controls, for all booster formulations, with an anti-D614G GMT ratio (98.3% CI) of 2.16 (1.69; 2.75) for MV(D614), an anti-B.1.351 ratio of 1.96 (1.54; 2.50) for MV (B.1.351) and anti-D614G and anti-B.1.351 ratios of 2.34 (1.84; 2.96) and 1.39 (1.09; 1.77), respectively, for BiV. All booster formulations elicited crossneutralizing antibodies against Omicron BA.2 across vaccine priming subgroups and against Omicron

- 25 BA.1 (evaluated in BNT162b2-primed participants). Similar patterns in antibody responses were
- 26 observed for participants aged \geq 56 years. No safety concerns were identified.
- 27 Conclusion
- 28 CoV2 preS dTM-AS03 boosters demonstrated acceptable safety and elicited robust neutralizing
- 29 antibodies against multiple variants, regardless of priming vaccine.
- 30 ClinicalTrials.gov: NCT04762680
- 31 **Funding:** Sanofi and federal funds from the Biomedical Advanced Research and Development
- 32 Authority (BARDA), part of the office of the Administration for Strategic Preparedness and Response
- 33 at the U.S. Department of Health and Human Services under Contract # HHSO100201600005I, and in
- 34 collaboration with the U.S. Department of Defense Joint Program Executive Office for Chemical,
- 35 Biological, Radiological and Nuclear Defense under Contract # W15QKN-16-9-1002.
- 36 Keywords: SARS-CoV-2, COVID-19, recombinant protein vaccine, AS03 adjuvant, booster,
- 37 immunogenicity, safety, Beta, B.1.351, Omicron

38 Introduction

39	The COVID-19 pandemic has seen an unprecedented deployment of COVID-19 vaccines. ¹⁻³ The
40	continued emergence of new variants of concern (VoC) of the severe acute respiratory syndrome
41	coronavirus 2 (SARS-CoV-2), together with waning immunity and protection against mild and
42	moderately symptomatic infection, underscore the need for new and updated booster vaccines to
43	enhance and broaden protection. ⁴⁻⁹ Bivalent boosters, targeting the prototype virus and Omicron
44	BA.1 or BA.4 and BA.5 subvariants have recently been authorized for use in the EU, USA and the
45	UK. ¹⁰⁻¹³ While Omicron variant-containing vaccines were designed to include the predominant
46	circulating strain, an alternative approach is to include strains that provide broad cross-protection
47	against emergent variants. ¹⁴
48	Sanofi and GSK have developed a SARS-CoV-2 recombinant protein vaccine with ASO3 adjuvant
49	(CoV2 preS dTM-AS03) using a baculovirus vector system to express stabilized SARS-CoV-2 pre-fusion
50	S protein (preS dTM). ¹⁵ In parallel with development of a D614 strain containing booster and primary
51	series vaccine ¹⁶ , we developed and are evaluating a CoV2 preS dTM-AS03 booster formulation
52	containing 5 μg of B.1.351 variant S protein (monovalent B.1.351) and a formulation containing 2.5
53	μg of D614 plus 2.5 μg of B.1.351 variants (bivalent D614+B.1.351). In previously primed non-human
54	primates, Beta (B.1.351) variant-containing adjuvanted recombinant protein vaccines showed broad
55	cross-reactivity across SARS-CoV-2 variants of concern and SARS-CoV-1. ^{17,18}
56	Here, we present interim safety and immunogenicity data for three CoV2 preS dTM-AS03 booster
57	formulations (monovalent D614, monovalent B.1.351 and bivalent D614+B.1.351) in participants
58	from our phase 3 cohorts, who were previously primed with authorized COVID-19 mRNA or
59	adenovirus-vectored vaccines, or with CoV2 preS dTM-AS03 (5, 10 or 15 μg of D614 antigen).

60 Methods

83

84

61 Study design and participants

62	In a substantial amendment to the Phase 2 primary series study (NCT04762680) ¹⁶ on June 10 2021,
63	two supplemental cohorts (cohort 1 and cohort 2) were added for phase 3 evaluation of the safety
64	and immunogenicity of monovalent D614, monovalent B.1.351 and bivalent D614+B.1.351 CoV2
65	preS dTM-AS03 booster formulations (Figure S1). Booster groups in both cohorts included adults
66	(≥18 years) from France, the USA, the UK, Australia and Spain who had completed a primary series of
67	an authorized or approved D614 mRNA vaccine (2 doses of BNT162b2 [30 μg; Pfizer/BioNTech] or
68	mRNA-1273 [100 µg; Moderna]) or adenovirus-vectored vaccine (2 doses of ChAdOx1 nCoV-19
69	[5×10 ¹⁰ vp; Oxford University/AstraZeneca] or 1 dose of Ad26.CoV2.S [5×10 ¹⁰ vp; J&J/Janssen]) at
70	least 4 months and no longer than 10 months prior to enrolment. Cohort 2 included a subgroup of
71	adults from the USA and Honduras who were previously primed in the original phase 2 study 4–10
72	months earlier with two doses of CoV2 preS dTM-AS03 containing 5, 10 or 15 μg of D614 antigen.
73	Cohort 1 included a parallel, non-randomized control group, encompassing unvaccinated adults, 18–
74	55 years of age, from the USA and Australia who tested negative for antibodies to SARS-CoV-2 with a
75	rapid diagnostic test (COVID-19 IgG and IgM Rapid Test Cassette; Healgen Scientific, Houston, TX,
76	USA). Individuals with pre-existing medical conditions, those who were immunocompromised
77	(except those with organ transplant in the past 180 days, chemotherapy in the past 90 days or with
78	HIV and CD4 counts <200/mm ³) and those with a potentially increased risk for severe COVID-19 ¹⁹
79	were eligible for participation in the study. The exclusion criteria are described in full in the
80	Supplementary Appendix, Methods. Vaccine administration was open-label in cohort 1 booster and
81	control groups and modified double-blind (observer-blinded) in cohort 2.
82	Participants were enrolled between 29 July 2021 and 22 October 2021 to cohort 1 and between 15
	Nevember 2021 and 22 Sebruary 2022 to sebert 2. Here we report interim immunescriptive data up
0.0	Nevershey 2021 and 22 February 2022 to schedt 2. Llevel via report interim immunation interimination of the un-

6

November 2021 and 22 February 2022 to cohort 2. Here, we report interim immunogenicity data up

to 14 days after last vaccination in all participants and safety data up to cut-off dates 18 February

2022 for cohort 1 and 13 May 2022 for cohort 2. For controls, long-term safety analyses were
conducted up to 13 May 2022.

87	The study was undertaken in compliance with the International Conference on Harmonization
88	guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki. The protocol
89	and amendments were approved by Independent Ethics Committees (country ethics committees for
90	Honduras [Comité Ética Independiente Zugueme], France [Comite De Protection Des Personnes Ile
91	De France III Hôpital Tarnier-Cochin, France], Spain [Comité De Éticade Investigación Con
92	Medicamentos Parc Taulï, Spain] and the UK [HRA and Health and Care Research Wales, UK], a
93	central ethics committee for the USA [Advarra] and local ethics committees for the USA [WCG IRB,
94	Columbia Research Human Research Protection Office, Langone Health Office of Science and
95	Research Institutional Review Board and the Yale Human Research Protection Program] and for
96	Australia [Bellberry, Sydney Children's Hospitals Network Human Research Ethics Committee and
97	Sydney Children's Hospital Network (SCHN) Research Governance]) as per local regulations. Written
98	informed consent was obtained from all participants before any study procedures were performed.
99	Procedures
100	Booster cohort participants were stratified by priming vaccine and by age category (18–55 years or
101	≥56 years) (Figure S1). In the cohort 1 booster groups, all participants were offered a dose of
102	monovalent D614. In cohort 2, participants primed with an mRNA or adenovirus-vectored vaccine
103	were randomized 1:1 to receive monovalent B.1.351 or bivalent D614+B.1.351 boosters; while those
104	previously primed with CoV2 preS dTM-AS03 (5, 10 or 15 μg of D614 antigen) were randomized 9:1
105	(18–55-year-olds) or 1:1 (≥56 year-olds) to receive monovalent D614 or monovalent B.1.351
106	boosters, respectively. Participants in the control group received two injections, 21 days apart (D1

and D22), of CoV2 preS dTM-AS03 containing 10 μg of D614 antigen.

108	The CoV2 preS dTM-AS03 vaccine was described previously. ^{15,16} Preparation of the booster

109 formulations and intramuscular administration are described in **Supplementary Methods**.

110 Immunogenicity

111 SARS-CoV-2 neutralizing antibody responses were measured using a lentivirus-based pseudovirus

112 neutralization (PsVN) assay expressing the full-length S protein of the SARS-CoV-2 D614G, Beta

113 (B.1.351) or Omicron (BA.1 or BA.2) variants (Monogram Biosciences LabCorp, South San Francisco,

- 114 CA, USA; **Supplementary Methods**).²⁰
- 115 Primary endpoints were individual serum PsVN titers at D1 and D15 against D614G for monovalent
- 116 D614 recipients, against B.1.351 for monovalent B.1.351 recipients, against D614G and B.1.351 for

117 bivalent D614+B.1.351 recipients, and against D614G 14 days after the last dose (D36) for the

118 control group. Secondary endpoints included PsVN titers against D614G and B.1.351 for each

119 predefined timepoint, the percentage of participants reaching a \geq 4-fold rise in serum neutralization

titer post-vaccination (D15 for booster cohorts; D22 and D36 for the control group) relative to pre-

121 vaccination (D1) and individual serum neutralization titer fold-rise. Exploratory endpoints included

122 individual serum PsVN titers against Omicron subvariants BA.2 and BA.1 in available samples across

all priming vaccine subgroups for BA.2 and from BNT162b2-primed participants for BA.1.

124 Safety

125 Safety was assessed for each treatment group and by age category (18–55 years or \geq 56 years).

126 Safety endpoints were as described in the original phase 2 study,¹⁶ with the list of AEs of special

127 interest (AESIs) updated to include anaphylactic reactions, generalized convulsions,

128 thrombocytopenia, thrombosis with thrombocytopenia syndrome, myocarditis, pericarditis and

129 potential immune-mediated diseases (pIMDs).^{21,22} Adverse events (AEs) were graded from grade 1

130 (mild) to grade 3 (severe; prevents normal daily activities) and assessed by the investigator as

131 related or unrelated to the study vaccine.

132 Statistics

133	Co-primary immunogenicity objectives were to demonstrate, for BNT162b2-primed participants 18–
134	55 years of age: i) the non-inferiority of post-booster D614G PsVN responses following monovalent
135	D614, post-booster B.1.351 PsVN responses following monovalent B.1.351 or both responses
136	following bivalent D614+B.1.351, compared to the D614G PsVN response elicited by primary
137	vaccination in the control group; and ii) the superiority of the post-booster relative to pre-booster
138	PsVN response. Statistical inference was based on the use of two-sided 98.3% Cls. Non-inferiority in
139	terms of neutralizing antibody titers was concluded if the lower bound of the 98.3% CI for the
140	between-group (booster versus control) GMT ratio was >0.67. Superiority in terms of neutralizing
141	antibody titers was concluded if the lower limit of the 2-sided 98.3% CI of the geometric mean of
142	individual ratio (GMTR; post-booster versus pre-booster) was >2. Study objectives are described in
143	more detail in the Supplementary Methods .
144	The per-protocol analysis set (PPAS) comprised all participants who received the booster injection or
145	both primary vaccinations (control group), who met all protocol inclusion and no exclusion criteria,
146	provided blood samples on D15 (booster cohorts) or D22 and D36 (control group), did not have pre-
147	specified protocol deviations and did not receive a COVID-19 vaccine outside of this study before
148	D15 (booster cohorts) or D36 (control group). Analyses in the control group were performed on
149	SARS-CoV-2 naïve participants from the PPAS. Naïve or non-naïve status was determined based on
150	serological detection of anti-S antibodies on D1 (S-ELECSYS; Elecsys Anti-SARS-CoV-2 S, Roche,
151	Indianapolis, IN, USA EUA202698) and nucleic-acid amplification test (NAAT; Abbott RealTime SARS-
152	CoV-2 assay, EUA200023) for detection of SARS-CoV-2 in nasopharyngeal swabs on D1 and D22
153	(Supplementary Methods). The safety analysis set (SafAS) comprised all participants who received at
154	least one study vaccine dose, with analysis according to the vaccine actually received.
155	For full details on statistical considerations, including planned sample sizes, see Supplementary

156 Methods. Statistical analyses were performed using SAS[®] Version 9.4 or later.

157 Results

158 **Participants and participant disposition**

159	Allocated booster doses were administered to 803 of 806 participants enrolled into the monovalent
160	D614 group, 705 of 707 participants enrolled into the monovalent B.1.351 group and 621 of 625

- 161 enrolled into the bivalent D614+B.1.351 group. In the control group, 473 of 479 enrolled SARS-CoV-
- 162 2-naïve participants received at least one primary dose of monovalent D614. A total of 18
- 163 monovalent D614 booster recipients, 34 monovalent B.1.351 booster recipients, 26 bivalent
- 164 D614+B.1.351 recipients and 43 participants in the control group discontinued the study before the
- analysis cut-off (Figure S2). The median interval between last primary and booster doses tended to
- 166 be slightly shorter overall for monovalent D614 recipients (5.75 months) than for monovalent
- 167 B.1.351 or bivalent D614+B.1.351 recipients (6.96 and 6.50 months, respectively) (Table 1). Across
- the three booster groups (SafAS), the mean age (standard deviation [SD]) ranged from 43.7 (14.3) to
- 169 50.4 (15.0) years; 22.2%–37.5% were ≥56 years old. Control group participants had a mean age of
- 170 37.5 (11.2) years. The majority of participants (65.5%–78.7% across booster and control groups)
- 171 were white. Across booster and control groups, 50.8%–59.8% of participants had at least one high-
- 172 risk medical condition (Table 1), of which obesity was the most common (Table S1). Among booster
- 173 groups in the PPAS, prior SARS-CoV-2 infection based on anti-nucleoprotein seropositivity was
- detected at baseline for 68/734 (9.3%) of monovalent D614 recipients, 138/615 (22.4%) of
- 175 monovalent B.1.351 recipients and 124/561 (22.1%) of bivalent vaccine recipients.

176 Immunogenicity

- 177 Monovalent D614 booster
- 178 Among participants aged 18–55 years, the D614G PsVN GMT for BNT162b2-primed participants

increased from 339 at D1 to 7894 (95% CI: 6993; 8911) on D15 following monovalent D614 booster,

demonstrating superiority of the PsVN response post-booster compared to pre-booster (post/pre-

181 booster ratio, 23.37 [98.3% CI: 18.58; 29.38]). PsVN titers against D614G at D15 were twice the level 182 of those induced after primary vaccination with CoV2 pres dTM-AS03 (D614) in the control group 183 (D36 GMT: 3658 [95% CI 3123; 4286]) demonstrating non-inferiority (GMT ratio of 2.16 [98.3% CI: 184 1.69; 2.75]) to the control group. Thus, the co-primary objectives for the monovalent D614 booster 185 group were met (Table 2A; see Table S3 for PsVN titers in the control group). 186 Non-inferiority versus the control group was demonstrated for the pooled mRNA vaccine-primed 187 group (GMT ratio, 2.09 [98.3% Cl: 1.66; 2.64]), the pooled adenovirus vectored vaccine-primed 188 group (GMT ratio, 1.89 [98.3% CI: 1.43; 2.49]) and the CoV2 preS dTM-AS03 (D614)-primed group 189 (GMT ratio, 7.27 [98.3% CI: 5.34; 9.89]). Superiority versus the pre-booster response was also 190 demonstrated for the mRNA-primed group (GMTR, 18.08 [98.3% CI: 14.75; 22.16]), for the 191 adenovirus-vectored primed group (GMTR, 30.18 [98.3% CI: 20.56; 44.31]) and the CoV2 preS dTM-192 AS03 (D614) group (GMTR, 51.63 [98.3% CI: 22.29; 119.57]) (Table 2A). The magnitude of D614G 193 PsVN titers at D15 following monovalent D614 booster in 18–55 year olds were similar in the mRNA 194 and adenoviral vectored priming groups but higher in the group primed with the CoV2 preS dTM-195 ASO3 (D614) vaccine (Figure 1A; Table S2). Seroresponse rates to D614G ranged from 71.2% to 196 93.1% across priming vaccine subgroups following monovalent D614 booster and was 99.0% (on 197 D36) in the control group among 18–55 year olds (Table S2).

198 A similar pattern in D614G PsVN titers was observed in older adults (≥56 years) (Figure S3). While

199 post-booster GMTs in older adults tended to be of a lower magnitude than those in younger adults,

200 they were still numerically higher than D36 GMTs post-primary vaccination in the control group, for

all vaccine-primed subgroups (Table S2).

202 Monovalent B.1.351 booster

203 In BNT162b2-primed participants aged 18–55 years, B.1.351 PsVN GMTs increased from 200 at D1 to

204 7172 (95% CI 6363; 8083) at D15 following a booster dose of monovalent B.1.351 (Figure 1B)

205	demonstrating superiority to pre-booster titers (D15/D1 titer ratio 35.41 [98.3% CI 26.71; 46.95])
206	(Table 2B). Comparing B.1.351 PsVN titers following the booster to those following primary
207	vaccination demonstrated non-inferiority to D614G PsVN antibody GMTs (GMT ratio, 1.96 [98.3% CI
208	1.54; 2.50]) and superiority to B.1.351 (GMTR, 17.36 [98.3% CI 13.39; 22.50]) (Table 2B).
209	Among participants aged 18–55 years, B.1.351 PsVN GMTs (95% CI) following monovalent B.1.351
210	booster increased from between 49.7 (32.7; 75.6) and 306 (114; 822) at D1 to between 5643 (4468;
211	7128) and 9146 (6734; 12421) at D15 across the mRNA and adenovirus-vectored priming vaccine
212	subgroups (Figure 1B). D15 GMTs were 1.5- to 2.5-fold higher than D614G PsVN GMTs following
213	primary vaccination in the control group. PsVN titers (95% CI) against D614G also increased in the
214	monovalent B.1.351 booster group (18–55 years age category) across the four mRNA or adenovirus-
215	vectored priming vaccine subgroups from between 165 (105; 258) and 1331 (917; 1931) at D1 to
216	between 6817 (5453; 8521) and 13189 (9836; 17684) at D15. Seroresponse rates to B.1.351 ranged
217	from 71.4% to 96.5% and those to D614G, from 63.6%–89.1% across priming vaccine subgroups
218	(Table S4).
219	PsVN GMTs against B.1.351 and D614G following monovalent B.1.351 booster also increased among
220	older adults (≥ 56 years), with D15 GMTs in all vaccine priming subgroups exceeding those following
221	primary vaccination in the control group (Figure S3; Table S4). D15 GMTs in older adults tended to
222	be lower than those in younger participants in all but the mRNA-1273-primed group. Notably, the
223	increase in post-booster PsVN titers following monovalent B.1.351 booster was particularly marked
224	for CoV2 preS dTM-AS03 (D614)-primed participants (≥56 years; N=68), with PsVN GMTs (95% CI)
225	rising to 24407 (17705; 33647) (anti-D614G) and 13180 (9571; 18151) (anti-B.1.351). This marked

- increase in titers was also seen in the 18–55 years age category for a small number (n=4) of
- 227 participants (Table S4).

228 Bivalent (D614+B.1.351) booster

229	Among BNT162b2-primed participants aged 18–55 years, PsVN GMTs (95% CI) to D614G increased
230	from 585 (477; 718) at D1 to 8550 (7638; 9571) at D15 and PsVN GMTs to B.1.351 increased from
231	151 (119; 191) at D1 to 5087 (4511; 5737) at D15 following a bivalent booster dose, demonstrating
232	superiority of D614G and B.1.351 booster responses at D15 compared to pre-booster (D15/D1
233	GMTRs [98.3% CI]: 14.39 [11.34; 18.28] and 34.18 [25.84; 45.22], respectively) (Figure 1C-D; Table
234	2C). The non-inferiority of PsVN titers against D614G and B.1.351 following bivalent booster
235	compared to post-primary D614G PsVN titers in the control group was also demonstrated, with GMT
236	ratios (98.3% CI) of 2.34 (1.84; 2.96) and 1.39 (1.09; 1.77), respectively. In addition, B.1.351 PsVN
237	titers induced by the bivalent booster were demonstrated to be superior to B.1.351 PsVN titers in
238	the control group (GMT ratio, 12.31 [98.3% CI: 9.50; 15.97]) (Table 2C).
239	Among 18–55 year olds, D614G and B.1.351 PsVN GMTs following the bivalent booster increased
240	substantially across all vaccine priming subgroups, with GMTRs (post-/pre-booster) ranging from 9 to
241	53 for anti-D614G and from 21 to 107 for anti-B.1.351 (Figure 1C-D). Seroresponse rates to D614G
242	ranged from 61.9% (48.8; 73.9) to 89.1% (77.8; 95.9) and those to B.1.351 ranged from 78.3 (95% CI:
243	56.3; 92.5) to 96.4% (95% CI: 87.7; 99.6) across subgroups (Table S5).
244	Increases in neutralizing antibody titers (against B.1.351 and against D614G) following the bivalent
245	D614+B.1.351 booster were also seen among older adults (≥56 years) (D15 GMTs: 2025–10035
246	[B.1.351]; 4492–22531 [D614G] across subgroups), with similar or lower PsVN titers compared to
247	younger adults in all but the Ad26.CoV2.S-primed subgroup, in which GMTs were higher in older
248	than younger adults (Table S5).
249	Neutralizing antibody responses to Omicron subvariant strains (exploratory analysis)
250	In a subset of participants aged 18–55 years (N=132 in the monovalent D614 booster; N=160 in the

- 251 monovalent B.1.351 group; N=156 in the bivalent booster group), baseline BA.2 PsVN titers were
- higher in the monovalent B.1.351 and bivalent groups than in the monovalent D614 group. Omicron

253	BA.2 PsVN GMTs increased 19 to 25-fold from baseline following booster, across the three booster
254	groups (Figure 2A) with the highest titers induced by the monovalent B.1.351 booster (2663 [95% CI:
255	2260; 3137]), followed by the bivalent booster (1810 [95% Cl: 1577; 2077]) and monovalent D614
256	booster (953 [95% Cl: 797; 1141]). In older adults (\geq 56 years) (N=74 in the monovalent D614
257	booster; N=59 in the monovalent B.1.351 group; N=33 in the bivalent booster group), while baseline
258	titers were comparable across booster groups, higher titers were elicited by the monovalent B.1.351
259	than by the other formulations. Similar results were obtained for booster responses against the
260	Omicron BA.1 subvariant in BNT162b2-primed participants (Figure 2B).

261 Safety

In each booster group, ≥98.0% of participants had completed at least 2 months of safety follow-up

by the analysis cut-off dates; the median duration of safety follow-up was 144–150 days across

booster groups. In the control group, 70.9% had completed ≥2 months safety follow-up and the

265 median duration was 148 days.

Adverse events for each booster formulation are summarized in **Table S6**. There were no immediate

267 unsolicited AEs reported in any booster group. Within 7 days after booster, grade 3 solicited

injection reactions were reported by 2.5% participants in the monovalent D614 booster group, 3.3%

in the monovalent B.1.351 group and 1.9% in the bivalent group (Figure 3); grade 3 solicited

systemic reactions were reported by 6.6%, 6.9% and 6.3%, respectively (Figure 4). Most solicited

271 reactions were transient (mostly lasting 1–3 days) and self-limited; all participants fully recovered.

272 Within 21 days after booster, 7.1–8.8% participants reported at least one unsolicited adverse

273 reaction. Across priming vaccine subgroups, solicited systemic reactions tended to be more

274 frequently reported for CoV2 preS dTM-AS03 (D614)-primed participants than for those primed with

other priming vaccines (Figure S4). Solicited and unsolicited events were mostly reactogenicity-type

events and generally more common in the 18–55 years than the ≥56 years group in both booster

277 cohorts (Supplementary Table S6).

278	One of 28 SAEs reported up to the analysis cut-off date was assessed as related to the study vaccine
279	(serum sickness-like reaction in a participant primed with mRNA-1273 and boosted with bivalent
280	D614+B.1.351), which resolved 11 days after onset following treatment (antihistamines and steroid
281	cream). One participant aged \geq 56 years, primed with CoV2 preS dTM-AS03 (D614) and boosted with
282	monovalent B.1.351, reported an AESI (trigeminal neuralgia), assessed as unrelated to vaccination.
283	Of 356 MAAEs reported by 264 booster recipients, eight (2 in the monovalent D614 group, 5 in the
284	monovalent B.1.351 group and 1 in the bivalent D614+B.1.351 group) were assessed as related to
285	the study vaccine. All MAAEs resolved. No deaths and no AEs leading to study discontinuation were
286	reported. No cases of unintentional exposure during pregnancy were reported in any booster group.
287	The safety profile of the control group is summarized in Supplementary Table S7 . Two participants
288	reported grade 3 immediate unsolicited AEs. One had grade 3 rash, assessed as related and non-
289	serious and resolved on the same day. Another had a grade 3 possible anaphylactic reaction
290	immediately after the second dose (also reported as an AESI and a MAAE), which was assessed as
291	related and resolved with treatment (intramuscular adrenaline and oral prednisone) on the same
292	day. This case did not meet the Brighton Collaboration case definition for anaphylaxis. ²³ Solicited
293	reactions were mostly mild to moderate and transient (Figure 3). Greater frequency and severity of
294	solicited systemic reactions were reported post-dose 2 compared to post-dose 1, with grade 3
295	solicited systemic reactions reported for 56/456 (12.3%) participants post-dose 1 and 76/377
296	(20.2%) post-dose 2 (Figure 4). Unsolicited AEs were mostly of mild or moderate intensity and
297	resolved within 7 days of onset. Eight participants reported eight SAEs in the control group, none
298	assessed as related. One SAE (suicidal ideation) led to study discontinuation. A second AESI (grade 1
299	rheumatoid arthritis) was reported 73 days post-second dose, assessed as not related. Of 121
300	MAAEs reported by 84 participants over the analysis period, 15 (in 8 participants), were assessed as
301	related; all resolved. No deaths were reported. One spontaneous abortion was reported in the
302	control group, assessed as not related to the vaccine. No other exposure during pregnancy was
303	reported in the control group.

304 Discussion

305	The findings from this study show that CoV2 preS dTM-AS03 booster vaccines (monovalent D614,
306	monovalent B.1.351 and bivalent D614+B.1.351) are well tolerated and elicit robust neutralizing
307	antibody responses against variants including Omicron in younger and older adults regardless of the
308	vaccine platform used for primary vaccination. Notably, greater neutralizing antibody responses
309	against Omicron BA.2 were achieved after boosting with monovalent B.1.351 than the other
310	formulations.
311	The cross-neutralization of Omicron subvariants following a Beta-variant containing vaccine
312	observed in this study is consistent with initial findings from a phase 3 randomized trial, in which a
313	booster dose of monovalent B.1.351 achieved higher neutralizing antibody titers against Beta, Delta
314	and Omicron BA.1 variants than either a monovalent D614 booster or a third dose of BNT162b2,
315	when administered to adults who previously received a primary vaccination series of BNT162b2. ²⁴
316	The cross-neutralization of Omicron subvariants with a Beta-variant containing vaccine has also been

317 observed with the mRNA vaccine platform. A bivalent mRNA COVID-19 vaccine candidate encoding

318 the ancestral SARS-CoV-2 and B.1.351 variant spike protein administered after a primary vaccination

319 series with the original mRNA-1273 elicited robust cross-neutralizing antibodies against Omicron.²⁵

320 This study benefits from a large global study population, inclusive of high-risk groups, thus closely

321 representing the potential target populations. The inclusion of participants previously primed with

322 different vaccine platforms (mRNA, adenovirus-vectored and adjuvant recombinant protein

323 vaccines) including globally deployed vaccines, allowed a comprehensive analysis of prime-boosting

324 options and make our findings applicable to a wide population of individuals. All three CoV2 preS

325 dTM-AS03 booster formulations elicited robust neutralizing antibody responses irrespective of

326 primary vaccination. While higher or similar responses have been previously reported for

heterologous prime-booster regimens with mRNA or adenovirus-vectored vaccines compared to

328 homologous prime-boost,²⁶⁻²⁸ the highest responses in the current study were observed following

329	prime-boost with CoV2 preS dTM-AS03 vaccine formulations. These findings may be influenced by
330	the variation in interval between primary and booster injections. Indeed, recent BNT162b2 booster
331	vaccination data suggest that a longer interval (35 weeks or more) may increase vaccine
332	effectiveness, ⁶ and previous data have suggested that extended intervals between doses in a
333	primary series of COVID-19 vaccination result in higher neutralizing antibody titers. ²⁹ Alternatively,
334	the higher booster responses following CoV2 preS dTM-AS03 priming may result from differences in
335	the priming of the immune system compared to the other priming vaccine platforms, or differences
336	in the proportion of participants who had prior infection.
337	Although rare, higher frequencies than expected of myocarditis and pericarditis have been
338	previously reported following receipt of COVID19 mRNA vaccines ³⁰ and with the adjuvanted,
339	protein-based vaccine NVX-CoV2373 ^{31,32} and an increased risk of thrombosis with
340	thrombocytopenia, following receipt of adenovirus-vectored vaccines. ³³ We did not identify any
341	safety concerns in the current study. For all booster groups, reactogenicity tended to be transient,
342	mild to moderate in severity, and similar (for solicited local reactions) or lower (for solicited systemic
343	reactions) post-booster than post-primary vaccination series. The proportion of participants
344	reporting a reactogenicity event after a CoV2 preS dTM-AS03 booster (any grade or grade 3) appears
345	to be similar to or less than that observed after licensed COVID-19 boosters (BNT162b2, mRNA-1273,
346	NVX-CoV2373). ³⁴⁻³⁶
347	Some limitations should be noted. Due to a lack of data on previous infection, we cannot make
348	meaningful direct comparisons across booster groups; also, we did not compare data for the \ge 56

349 years age category to age-matched controls. The variability in the interval between last primary

350 vaccine dose and booster may have affected the antibody responses to booster vaccination;

- similarly, the inclusion of immunocompromised participants in our study may have affected the
- immune responses observed. While our immunogenicity results are promising, it will be important
- 353 to evaluate the durability of the responses observed in this study, beyond the 15 days post-booster

354	period. Additionally, data on efficacy, as well as on cellular responses elicited by these vaccines, will
355	be needed to understand their potential effectiveness against disease outcomes. Another limitation
356	of our study is the lack of cross-neutralization data on BA.4/5 and more recent variants such as
357	BQ.1.1 and BA.2.75. However, while at the time of writing, the dominant global VoC are Omicron
358	subvariants BA.4 and BA.5, ³⁷ the nature of likely future SARS-CoV-2 variants remains unpredictable.
359	Our data indicate that a vaccine containing a B.1.351-component can provide cross-neutralization
360	against a heterologous emergent strain and challenges the current variant-chasing vaccine
361	paradigm.
362	In summary, B.1.351-containing CoV2 preS dTM-AS03 vaccines given as a booster following primary
363	vaccination with globally deployed vaccines elicited strong cross-neutralizing antibody responses

- against SARS-CoV-2 variants, including against Omicron variants, and had acceptable safety profiles.
- 365 These findings support the deployment of monovalent B.1.351 as a universal booster against COVID-

366 19.

367 Author Contributions

368	GdB, MAC, FTDS, BF, MHG, OH, MK, NLM, RMC, NR, LS, SG, SSa and SSr contributed to the concept
369	or design of the study and data analysis and interpretation; MIB and RM contributed to the
370	conception or design of the study and data acquisition; MSR, HA, SA, DB, AB, RC, SD, DD, AF, RF, JG,
371	PG, DH, OL, JAH, FMT, JP, DMRM, CR, LDS and AW contributed to data acquisition; AP and JW were
372	involved in the analysis and interpretation of the data. All authors were involved in drafting or
373	critically revising the manuscript, and all authors approved the final version and are accountable for
374	the accuracy and integrity of the manuscript. All authors had full access to all the data and accept
375	responsibility to submit for publication.

376 Declaration of Interests

377 GdB, JW, AP, MSR, HA, MIB, RC, RF, BF, JG, M-HG, SG, OH, RM, JP, NR, RMC and SSa are Sanofi

employees; MIB, RMC hold stock options. SSa was a Sanofi employee at the time of study conduct.

379 SSr, RMC, GdB, CAD and SSa, are inventors on a pending patent application filed by Sanofi and GSK

380 for the development of the CoV-2 dTM vaccine. MAC, LS and MK are employed by GSK and hold

381 restricted shares in the GSK group of companies. FTDS was employed by GSK, and held restricted

382 shares in the GSK group of companies, at the time of the study. DMRM declares that her institution

received funding from Sanofi. FM-T has received honoraria from GSK group of companies, Pfizer Inc,

- 384 Sanofi, MSD, Seqirus, Biofabri, and Janssen for taking part in advisory boards and expert meetings
- and for acting as a speaker in congresses outside the scope of the submitted work. FM-T has also

acted as principal investigator in randomized controlled trials of the above-mentioned companies as

387 well as Ablynx, Gilead, Regeneron, Roche, Abbott, Novavax, and MedImmune, with honoraria paid

to his institution. AF receives research funding, paid to his employers, from Sanofi both for work

related to this study and other unrelated vaccine trials and from GSK for other unrelated studies. He

390 receives research funding from other vaccine manufacturers relating to trials and studies and

391 undertakes paid consultancy related to a number of developmental antimicrobial drugs and

392 vaccines.

393 Data sharing statement

- 394 Qualified researchers can request access to patient-level data and related study documents,
- including the clinical study report, study protocol with any amendments, blank case report forms,
- 396 statistical analysis plan, and dataset specifications. Patient-level data will be anonymised and study
- 397 documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's
- data sharing criteria, eligible studies, and process for requesting access can be found at
- 399 https://vivli.org/.

400 Acknowledgements

- 401 The authors thank all participants, investigators, and study site personnel who took part in this
- 402 study. The authors acknowledge Juliette Gray of inScience Communications, Springer Healthcare,
- 403 London, UK, for providing editorial assistance with the preparation of this manuscript, funded by
- 404 Sanofi. The authors also thank Hanson Geevarghese for providing manuscript coordination on behalf
- 405 of Sanofi. This work was done in collaboration with GSK, who provided access to, and use of, the
- 406 AS03 Adjuvant System.

407 Role of the funding source

Funding was provided by Sanofi and by federal funds from the Biomedical Advanced Research and Development Authority, part of the office of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services under Contract # HHSO100201600005I, and in collaboration with the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense under Contract # W15QKN-16-9-1002. The funders were involved in the study design, data collection, data analysis,

- 414 data interpretation, writing of the report, and the decision to submit the paper for publication. GSK
- 415 provided access to, and use of, the ASO3 Adjuvant System.

References

1. Ssentongo P, Ssentongo AE, Voleti N, et al. SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis. BMC infectious diseases 2022;22:439.

2. Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morbidity and mortality weekly report 2022;71:139-45.

3. Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nature Medicine 2022;28:1063-71.

4. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Available at https://covid19.who.int/. Accessed 29 March 2022.

5. World Health Organization. Interim statement on decision-making considerations for the use of variant updated COVID-19 vaccines. Available at https://www.who.int/news/item/17-06-2022-interim-statement-on-decision-making-considerations-for-the-use-of-variant-updated-covid-19-vaccines. Accessed 27 September 2022. 2022.

6. Andrews N, Stowe J, Kirsebom F, et al. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. Nature Medicine 2022.

7. Bar-On YM, Goldberg Y, Mandel M, et al. Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. N Engl J Med 2022;386:1712-20.

8. Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION

Network, 10 States, August 2021-January 2022. MMWR Morbidity and mortality weekly report 2022;71:255-63.

9. Menni C, May A, Polidori L, et al. COVID-19 vaccine waning and effectiveness and sideeffects of boosters: a prospective community study from the ZOE COVID Study. The Lancet Infectious Diseases 2022;22:1002-10.

10. European Medicines Agency. First adapted COVID-19 booster vaccines recommended for approval in the EU. Available at https://www.ema.europa.eu/en/news/first-adapted-covid-19-booster-vaccines-recommended-approval-eu. Accessed 14 September 2022.

11. U.S. Food & Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose. Available at <u>https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-</u> authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use. Accessed 14 September 2022.

12. UK Medicines and Healthcare products Regulatory Agency. Press release: First bivalent COVID-19 booster vaccine approved by UK medicines regulator. Available at <u>https://www.gov.uk/government/news/first-bivalent-covid-19-booster-vaccine-approved-by-uk-</u> medicines-regulator. Accessed 14 September 2022.

13. UK Medicines and Healthcare products Regulatory Agency. Press release: Pfizer/BioNTech bivalent COVID-19 booster approved by UK medicines regulator. Available at https://www.gov.uk/government/news/pfizerbiontech-bivalent-covid-19-booster-approved-by-uk-medicines-regulator. Accessed on 14 September 2022.

14. Sridhar S, Chicz RM, Warren W, et al. The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022. Nature Communications 2022;13:5794.

15. Goepfert PA, Fu B, Chabanon AL, et al. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study. Lancet Infect Dis 2021:1257-70.

16. Sridhar S, Joaquin A, Bonaparte MI, et al. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study. Lancet Infect Dis 2022.

17. Corbett KS, Gagne M, Wagner DA, et al. Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. Science 2021;374:1343-53.

18. Pavot V, Berry C, Kishko M, et al. Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates. Nat Commun 2022;13:1699.

19. Centers for disease control and prevention. Underlying Medical Conditions Associated with High Risk for Severe COVID-19: Information for Healthcare Providers. Available at <u>https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html</u>. Accessed on 30 April 2021. 2021.

20. Petropoulos CJ, Parkin NT, Limoli KL, et al. A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1. Antimicrobial Agents and Chemotherapy 2000;44:920-8.

21. Tavares Da Silva F, De Keyser F, Lambert P-H, Robinson WH, Westhovens R, Sindic C. Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines. Vaccine 2013;31:1870-6.

22. Barbara Law. Safety Platform for Emergency Vaccines. SO2-D2.1.2 Priority list of COVID-19 adverse events of special interest: quarterly update December 2020. The Coalition for Epidemic Preparedness Innovations (CEPI) and the Brighton Collaboration; December 23, 2020. Available at https://brightoncollaboration.us/wp-content/uploads/2021/01/SO2_D2.1.2_V1.2_COVID-19_AESI-update-23Dec2020-review_final.pdf. Last accessed November 29, 2022.2020.

23. Law B. SO2- D2.5.2.1 – AESI Case Definition Companion Guide for 1st Tier AESI. Available at https://brightoncollaboration.us/wp-content/uploads/2021/03/SPEAC_D2.5.2.1_Anaphylaxis-Case-Definition-Companion-Guide_V1.0-12070-1.pdf. Accessed 31 May 2022.2021.

24. Launay O, Cachanado M, Luong Nguyen LB, et al. Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine. New England Journal of Medicine 2022;387:374-6.

25. Chalkias S, Eder F, Essink B, et al. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine. Nature Medicine 2022;28:2388–97.

26. Atmar RL, Lyke KE, Deming ME, et al. Homologous and Heterologous Covid-19 Booster Vaccinations. New England Journal of Medicine 2022;386:1046-57.

27. Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. The Lancet 2021;398:2258-76.

28. Mayr FB, Talisa VB, Shaikh O, Yende S, Butt AA. Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans. New England Journal of Medicine 2022.

29. Martinez DR, Ooi EE. A potential silver lining of delaying the second dose. Nature Immunology 2022;23:349-51.

30. Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021. MMWR Morbidity and mortality weekly report 2021;70:977-82.

31. Department of Health and Aged Care AG. Nuvaxovid (Novavax). Available at https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/approved-vaccines/novavax. Accessed 16 November 2022.

32. Twentyman E, Wallace M, Roper LE, et al. Interim Recommendation of the Advisory
 Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥
 18 years - United States, July 2022. MMWR Morbidity and mortality weekly report 2022;71:988-92.

33. Li X, Burn E, Duarte-Salles T, et al. Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US. BMJ 2022;379:e071594.

34. Choi A, Koch M, Wu K, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nature medicine 2021;27:2025-31.

35. Mallory RM, Formica N, Pfeiffer S, et al. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. Lancet Infect Dis 2022.

U.S. Food and Drug Administration. Application for licensure of a booster dose for
 COMINARTY (COVID-19 vaccine, mRNA). BNT162b2: evaluation of a booster dose (third dose). Sept
 17, 2021. <u>https://www.fda.gov/media/152176/download</u>. Accessed October 25, 2022.

37. Tracking SARS-CoV-2 variants. Available at <u>https://www.who.int/activities/tracking-SARS-</u> <u>CoV-2-variants</u>. Updated on 25 May 2022. Accessed 01 June 2022.

Tables and Figures

Table 1: Participant demographic characteristics (SafAS)

	CoV2	Control group		
	Monovalent D614 N=803	Monovalent B.1.351 N=705	Bivalent D614+B.1.351 N=621	- (two monovalent D614 primary vaccine does) N=473
Sex, n (%)				
Female	434 (54.0)	367 (52.1)	330 (53.1)	210 (44.4)
Male	369 (46.0)	338 (47.9)	291 (46.9)	263 (55.6)
Age, years				
Mean (SD)	50.4 (15.0)	46.0 (15.8)	43.7 (14.3)	37.5 (11.2)
Median (range)	51.0 (18.0; 88.0)	47.0 (18.0; 93.0)	43.0 (18.0; 80.0)	38.0 (18.0; 66.0)
Age category, n (%)				
18-55 years	502 (62.5)	492 (69.8)	483 (77.8)	459 (97.0)
≥56 years	301 (37.5)	213 (30.2)	138 (22.2)	14 (3.0)
Country, n (%)				
Australia	0	39 (5.5)	32 (5.2)	288 (60.9)
France	144 (17.9)	113 (16.0)	116 (18.7)	0
Honduras	43 (5.4)	37 (5.2)	0	0
Spain	0	44 (6.2)	38 (6.1)	0
UK	94 (11.7)	101 (14.3)	110 (17.7)	0
US	522 (65.0)	371 (52.6)	325 (52.3)	185 (39.1)
Race, n (%)				
American Indian or Alaska Native	28 (3.5)	29 (4.1)	10 (1.6)	15 (3.2)
Asian	39 (4.9)	21 (3.0)	25 (4.0)	18 (3.8)
Black or African American	32 (4.0)	91 (12.9)	104 (16.7)	50 (10.6)
Native Hawaiian or Other Pacific Islander	0	3 (0.4)	1 (0.2)	0
White	632 (78.7)	468 (66.4)	407 (65.5)	370 (78.2)
Multiracial	2 (0.2)	10 (1.4)	8 (1.3)	8 (1.7)
Not reported	43 (5.4)	46 (6.5)	58 (9.3)	3 (0.6)
Unknown	27 (3.4)	37 (5.2)	8 (1.3)	9 (1.9)

Ethnicity, n (%)				
Hispanic or Latino	112 (13.9)	103 (14.6)	71 (11.4)	26 (5.5)
Not Hispanic or Latino	656 (81.7)	487 (69.1)	457 (73.6)	390 (82.5)
Not reported	34 (4.2)	102 (14.5)	85 (13.7)	50 (10.6)
Unknown	1 (0.1)	13 (1.8)	8(1.3)	7 (1.5)
≥1 High-risk medical condition, n (%)				
Yes	408 (50.8)	415 (58.9)	364 (58.6)	283 (59.8)
No	395 (49.2)	290 (41.1)	257 (41.4)	190 (40.2)
Priming vaccine, n (%)				
BNT162b2	328	378	375	na
mRNA-1273	113	111	108	na
ChAdOx1nCoV-19	127	100	100	na
Ad26.CoV2.S	103	38	38	na
CoV2 preS dTM-AS03 (D614)	132	78	na	na
Median interval (IQR), last priming vaccine dose to booster, months	5.75 (4.73; 7.33)	6.96 (5.68; 8.15)	6.50 (5.52; 7.79)	na

IQR=interquartile range (Q1-Q3); na, not applicable; SafAS = safety analysis set.

Table 2. Non-inferiority and superiority of PsVN titers against D614G and B.1.351 following monovalent and bivalent boosters compared with CoV2 preS

dTM-AS03 (D614) primary vaccination or compared with pre-booster PsVN titers - PPAS

A. Monovalent D614 booster group

Priming vaccine or vaccine platform subgroup	Booster D15 Control D		D36	Post-booster vs control				Post	Post-booster vs pre-booster		
	Strain	М	Strain	М	GMT ratio	98.3% CI	NI*	М	GMTR	98.3% CI	Superiority†
BNT162b2	D614G	202	D614G	302	2.16	1.69; 2.75	Yes	189	23.37	18.58; 29.38	Yes
mRNA vaccine platform	D614G	269	D614G	302	2.09	1.66; 2.64	Yes	255	18.08	14.75; 22.16	Yes
Pooled Ad virus vectored platform	D614G	131	D614G	302	1.89	1.43; 2.49	Yes	108	30.18	20.56; 44.31	Yes
CoV2 preS dTM-AS03 (D614)	D614G	52	D614G	302	7.27	5.34; 9.89	Yes	45	51.63	22.29; 119.57	Yes

B. Monovalent B.1.351 booster group

Priming vaccine or vaccine platform subgroup	Booster D15 Co		Control	Control D36		Post-booster vs control			Post-	Post-booster vs pre-booster		
	Strain	М	Strain	М	GMT ratio	98.3% CI	NI*	М	GMTR	98.3% CI	Superiority†	
BNT162b2	B.1.351	279	D614G	302	1.96	1.54; 2.50	Yes	256	35.41	26.71; 46.95	Yes	
	B.1.351	279	B.1.351	291	17.36	13.39; 22.50	Yes‡	-	-	-	-	
mRNA vaccine platform	B.1.351	347	D614G	302	2.06	1.62;2.61	Yes	321	34.19	26.58 ; 43.98	Yes	

C. Bivalent D614+B.1.351 booster group

Priming vaccine or vaccine platform subgroup	Booster D15		Control D36		Post-booster vs control				Post-booster vs pre-booster		
	Strain	М	Strain	М	GMT ratio	98.3% CI	NI*	М	GMTR	98.3% CI	Superiority†
BNT162b2	D614G	276	D614G	302	2.34	1.84; 2.96	Yes	269	14.39	11.34; 18.28	Yes
	B.1.351	276	D614G	302	1.39	1.09; 1.77	Yes	248	34.18	25.84; 45.22	Yes
	B.1.351	276	B.1.351	291	12.31	9.50; 15.97	Yes‡	-	-	-	-
mRNA vaccine platform	D614G	343	D614G	302	2.52	2.00;3.16	Yes	332	13.04	10.56 ; 16.11	Yes
	B.1.351	342	D614G	302	1.47	1.16 ; 1.85	Yes	309	31.19	24.33 ; 39.97	Yes

D, study day; M, number of participants with available data for the analysis; NI, non-inferiority

*Non-inferiority of a booster response against D614G or B.1.351 compared to a response against D614G in the control group was concluded if the lower bound of the 98.3% CI for the between-group (booster versus control) GMT ratio was >0.67.


†Superiority of a booster response compared to a pre-booster response was concluded if the lower limit of the 2-sided 98.3% CI of the fold-rise (post-booster versus pre-booster) was >2.

[‡]Superiority, rather than non-inferiority, was demonstrated for this comparison (conditional secondary objective). The superiority of a booster dose response against B.1.351 of monovalent B.1.351 or bivalent D614+B.1.351 in BNT162b2 primed participants aged 18-55 years compared to a response against B.1.351 in the control group was concluded if the lower limit of the 2-sided 98.3% CI of the ratio of GMTs between groups was > 1.5.

It is made available under a CC-BY-NČ 4.0 International license . Figure 1. Booster pseudovirus neutralizing antibody responses against D614G or B.1.351 strains for (A) monovalent


D614, (B) monovalent B.1.351 and (C and D) bivalent D614+B.1.351 among 18–55 year olds, by prior priming vaccine –


PPAS




A. Monovalent D614 booster (D614G PsVN titers)


C. Bivalent D614+B.1.351 (D614G PsVN titers)





B. Monovalent B.1.351 (B.1.315 PsVN titers)





Number of participants in each priming group, 18–55 years

Booster group	Strain	BNT		Mod ChAd		A	d26	AS03	-CoV2		
		D1	D15	D1	D15	D1	D15	D1	D15	D1	D15
MV D614	D614G	189	202	66	67	58	68	50	63	45	52
MV B.1.351	B.1.351	256	279	65	68	57	62	22	21	4	4
	D614G	274	279	68	68	55	62	22	22	4	4
BiV	B.1.351	249	276	62	66	57	57	23	25	-	-
	D614G	270	276	64	67	56	57	24	25	-	-

Graphs are annotated with geometric mean titers (above each bar) and geometric means of individual titer ratios (above grouped bars), calculated based on paired post-vaccination/pre-vaccination results. Error bars denote 95% CIs for the GMTs. *95% confidence not calculated due to small number of participants analyzed (n=4). Table shows number of participants with available data for at each timepoint.

D1, study day 1 (pre-booster); D15, study day 15 (14 days post-booster); BNT, BNT162b2-primed; Mod, mRNA-1273primed; ChAd, ChAdOx1nCoV-19-primed; Ad26, Ad26.CoV2.S-primed; AS03-CoV2, CoV2 preS dTM-AS03 (D614)-primed

10000]

1000

100 -

10

1

ID50 titer (BA.2)


X 27

28

775


Omicron BA.2 and (B) BA.1, by age category


A. Omicron BA.2



B. Omicron BA.1







44

≥ 56 years

X 72


3594

X 18

64

1277





D1

Number of participants	


Number of participants											
Omicron subvariant	Age group	MV D614		MV B	.1.351	BiV					
		D1	D15	D1	D15	D1	D15				
BA.2*	18-55 yr	110	130	135	159	132	155				
	≥56 yr	65	70	53	59	30	33				
BA.1†	18-55 yr	18	18	20	20	20	19				
	≥56 yr	20	17	10	11	17	17				

MV, monovalent; BiV, bivalent

Graphs are annotated with geometric mean titers (above each bar) and geometric means of individual titer ratios (above grouped bars), calculated based on paired post-vaccination/pre-vaccination results. Error bars denote 95% CIs for the GMTs, calculated using normal approximation of log-transformed titers. Table shows number of participants with available data for at each timepoint. *Assessed on available samples across priming vaccine subgroups; †Assessed on available samples in the BNT162b2-primed subgroup


Figure 3. Solicited injection site reactions up to 7 days following vaccination in CoV2 preS dTM-AS03 booster groups and the control group, by age category - SafAS

A. Booster groups



18–55 years age group

B. Control group




The percentages of participants experiencing at least one of the specified reactions are shown. Error bars denote 95% Cls for the percentages after any injection, calculated using the Clopper-Pearson method. MV, monovalent; BiV, bivalent


≥56 years age group

Figure 4. Solicited systemic reactions up to 7 days following vaccination in CoV2 preS dTM-AS03 booster groups and the control group, by age category – SafAS

A. Booster groups



B. Control group



The percentages of participants experiencing at least one of the specified reactions are shown. Error bars denote 95% CIs for the percentages after any injection, calculated using the Clopper-Pearson method.

MV, monovalent; BiV, bivalent